Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
暂无分享,去创建一个
Cameron R. Wolfe | A. Amin | M. Proschan | L. Dodd | R. Davey | A. Mehta | S. de Bono | B. Taiwo | V. Marconi | N. Rouphael | N. Ahuja | R. Mularski | A. Kalil | M. Oh | R. Finberg | G. Ruiz-Palacios | A. Branche | J. Beigel | D. Sweeney | V. Tapson | D. Lye | N. Iovine | S. Tan | B. Taylor | A. Luetkemeyer | S. Kline | Stuart H. Cohen | K. Tomashek | L. Hsieh | T. Patterson | T. Burgess | Tyler Bonnett | Michelle L. Green | Mat Makowski | S. Nayak | J. Billings | V. Ghazaryan | U. Sandkovsky | E. Ko | G. Deye | E. S. Kim | J. Engemann | Marie-Carmelle Elie | Mamta K. Jain | Hana M. El Sahly | H. E. El Sahly | J. Ferreira | H. Nielsen | V. Cantos | Miki Watanabe | A. Cardoso | Youssef Saklawi | H. Arguinchona | L. Larson | P. Goepfert | Justino Regalado Pineda | Patrick E H Jackson | Catherine I Paules | M. Frank | P. Ponce | Walla Dempsey | M. Jain | Catherine I. Paules | M. Makowski | Michelle Green | Philip O Ponce | Neera Ahuja | John J. Engemann | Philip O. Ponce | Nicole M. Iovine
[1] J. L. Rodríguez-García,et al. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study , 2020, Rheumatology.
[2] Jennifer S. Wood,et al. Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques , 2020, bioRxiv.
[3] R. Higgs,et al. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.
[4] W. Schaffner,et al. Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System , 2020, medRxiv.
[5] R. Schinazi,et al. Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] P. Lotti,et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study , 2020, The Journal of Infection.
[7] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[8] Michael Proschan,et al. Endpoints for randomized controlled clinical trials for COVID-19 treatments , 2020, Clinical trials.
[9] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[10] E. Nicastri,et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact , 2020, Journal of Infection.
[11] F. Baldanti,et al. Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients , 2020, EMBO molecular medicine.
[12] A. Kalil. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. , 2020, JAMA.
[13] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[14] Ivan Griffin,et al. COVID-19: combining antiviral and anti-inflammatory treatments , 2020, The Lancet Infectious Diseases.
[15] A. Phelan,et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease , 2020, The Lancet.